Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
45.53 ^USD	+20.16%		+21.28%	+13.12%

Apr. 29	Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	MT
Apr. 29	Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline	DJ

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

February 22, 2024 at 08:01 am EST

REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44^th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

Primary Logo

Source: Soleno Therapeutics

2024 GlobeNewswire, Inc., source Press Releases

Latest news about Soleno Therapeutics, Inc.

Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	Apr. 29	MT
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline	Apr. 29	DJ
Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome	Apr. 29	CI
Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing	Apr. 04	MT
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Soleno Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Piper Sandler Starts Soleno Therapeutics With Overweight Rating, $93 Price Target	Feb. 05	MT
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	Jan. 24	MT
Soleno Therapeutics Strengthens Leadership Team with Key Appointments	Jan. 24	CI
Stifel Starts Soleno Therapeutics With Buy Rating, $63 Price Target	Jan. 23	MT
Soleno Therapeutics Files Mixed Shelf	Jan. 03	MT
Oppenheimer Lifts Price Target on Soleno Therapeutics to $47 From $44, Maintains Outperform Rating	Jan. 02	MT
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) added to S&P Biotechnology Select Industry Index	Dec. 18	CI
Soleno Therapeutics Insider Sold Shares Worth $1,412,431, According to a Recent SEC Filing	Dec. 15	MT
Soleno Therapeutics Insider Sold Shares Worth $1,182,828, According to a Recent SEC Filing	Dec. 14	MT
Soleno Therapeutics Insider Sold Shares Worth $222,177, According to a Recent SEC Filing	Dec. 01	MT
Soleno Therapeutics Insider Sold Shares Worth $1,471,049, According to a Recent SEC Filing	Dec. 01	MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $44 From $39, Maintains Outperform Rating	Nov. 09	MT
Soleno Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome	Nov. 06	CI
Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding	23-10-03	CI
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	23-10-03	MT
Soleno Therapeutics Closes $69 Million Public Stock Offering	23-10-02	MT
Soleno Therapeutics, Inc. announced that it expects to receive $59.98825 million in funding	23-10-01	CI

Chart Soleno Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCRâs mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.53 USD

Average target price

64.33 USD

Spread / Average Target

+41.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOLENO THERAPEUTICS, INC.	+13.12%	1.27B
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs